Myelitis  >>  Avonex (recombinant IFN-β-1a)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Avonex (recombinant IFN-β-1a) / Biogen
NCT00037115: Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.

Withdrawn
4
0
US
interferon beta 1a, methotrexate, methylprednisolone
MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute, Consultants in Neurology
Demyelinating Disorders, Multiple Sclerosis, Optic Neuritis, Myelitis, Neuritis
12/02
12/02
CHAMPIONS10, NCT00179478: Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis

Checkmark Data - ACTRIMS 2012
Jun 2012 - Jun 2012: Data - ACTRIMS 2012
Completed
4
155
US, Canada
interferon beta 1a 30 ug IM once weekly
Beth Israel Deaconess Medical Center, Biogen
Multiple Sclerosis, Optic Neuritis, Transverse Myelitis, Acute Brainstem/Cerebellar Syndrome
03/09
03/09

Download Options